Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response.
Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, Sarrazin C, Balciuniene L, Feinman SV, Faruqi R, Pedicone LD, Esteban R; SUCCESS Study Investigators. Buti M, et al. Among authors: faruqi r. Hepatology. 2010 Oct;52(4):1201-7. doi: 10.1002/hep.23816. Hepatology. 2010. PMID: 20683847 Clinical Trial.
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.
Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, Klinker H, Buggisch P, Rössle M, Hinrichsen H, Merican I, Ilan Y, Mauss S, Abu-Mouch S, Horban A, Müller TH, Welsch C, Chen R, Faruqi R, Pedicone LD, Wedemeyer H. Manns M, et al. Among authors: faruqi r. J Hepatol. 2011 Sep;55(3):554-563. doi: 10.1016/j.jhep.2010.12.024. Epub 2011 Jan 13. J Hepatol. 2011. PMID: 21237227 Clinical Trial.
Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response.
Craxi A, Koutsounas S, Ogurtsov P, Chemello L, Maticic M, Torras J, Diago M, Tartaglione MT, Witthoeft T, Yu X, Faruqi R, Chaudhri E, Pedicone LD, Zuckerman E. Craxi A, et al. Among authors: faruqi r. J Viral Hepat. 2012 Feb;19(2):e120-5. doi: 10.1111/j.1365-2893.2011.01515.x. Epub 2011 Sep 19. J Viral Hepat. 2012. PMID: 22239509 Clinical Trial.
Respiratory disease in the Asia-Pacific region: Cough as a key symptom.
Cho SH, Lin HC, Ghoshal AG, Bin Abdul Muttalif AR, Thanaviratananich S, Bagga S, Faruqi R, Sajjan S, Brnabic AJ, Dehle FC, Wang de Y. Cho SH, et al. Among authors: faruqi r. Allergy Asthma Proc. 2016 Mar-Apr;37(2):131-40. doi: 10.2500/aap.2016.37.3925. Epub 2016 Jan 21. Allergy Asthma Proc. 2016. PMID: 26802834
Burden of respiratory disease in Thailand: Results from the APBORD observational study.
Thanaviratananich S, Cho SH, Ghoshal AG, Muttalif ARBA, Lin HC, Pothirat C, Chuaychoo B, Aeumjaturapat S, Bagga S, Faruqi R, Sajjan S, Baidya S, Wang Y. Thanaviratananich S, et al. Among authors: faruqi r. Medicine (Baltimore). 2016 Jul;95(28):e4090. doi: 10.1097/MD.0000000000004090. Medicine (Baltimore). 2016. PMID: 27428193 Free PMC article.
41 results